We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Scripps Tumorgraft Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01726699
First Posted: November 15, 2012
Last Update Posted: April 3, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute
  Purpose
Study the genetic traits of cancerous tissues and to help improve cancer treatment by developing tumor models for studying new cancer drugs.

Condition
Solid Tumor Malignancy or Hematologic Malignancy

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Scripps Tumorgraft Study

Further study details as provided by Eric Topol, MD, Scripps Translational Science Institute:

Primary Outcome Measures:
  • Facilitate the development of individualized tumorgraft models for many different types of cancer. [ Time Frame: 3 years ]

Biospecimen Retention:   Samples With DNA
Blood and tissue samples

Enrollment: 11
Study Start Date: November 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts
Cancer Diagnosis

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adults with a solid tumor malignancy or a hematologic malignancy
Criteria

Inclusion Criteria:

  • Age 21 or over
  • diagnosis of a solid tumor malignancy, either resectable or metastatic or a hematologic malignancy
  • cognitively and emotionally able to give informed consent

Exclusion Criteria:

  • Under age 21
  • Not cognitively or emotionally able to give informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01726699


Locations
United States, California
Scripps Translational Science Institute
La Jolla, California, United States, 92037
Sponsors and Collaborators
Scripps Translational Science Institute
Investigators
Principal Investigator: Laura Goetz, MD Director, Applied Genetic Epidemiology
  More Information

Responsible Party: Eric Topol, MD, Director, Applied Genetic Epidemiology, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01726699     History of Changes
Other Study ID Numbers: 12-6011
First Submitted: November 6, 2012
First Posted: November 15, 2012
Last Update Posted: April 3, 2015
Last Verified: April 2015

Additional relevant MeSH terms:
Neoplasms